Epalrestat

Research use only, not for human use.

A noncompetitive and reversible aldose reductase inhibitor with IC50 of 10 nM and 26 nM for purified aldose reductase from rat lens and human placenta, respectively.

A noncompetitive and reversible aldose reductase inhibitor with IC50 of 10 nM and 26 nM for purified aldose reductase from rat lens and human placenta, respectively; used for the treatment of diabetic neuropathy.Diabetes Approved.

RT-PCR Cell Line:rat SCs Concentration:10 or 50 μM Incubation Time:4 h Result:Increased the nuclear level of active Nrf2 by 1.8- and 3.8-fold at 10 and 50 μM, and failed to increase Nrf2 mRNA levels.

Animal Model:db/db mice Dosage:0.08% (w/w) in fed regular chow Administration:8 weeks Result:Ameliorated GBM thickening and mesangial matrix deposition in kidney tissue.Reduced the elevated sorbitol and fructose in the plasma, urine, and renal cortex of db/db mice.Reduced myo-inositol in the plasma and urine, whereas increased myo-inositol in the renal cortex.Animal Model:Rats were treated with high-fat and high-sugar diet for 4 weeks, and injected with Streptozotocin at 4 and 8 weeks Dosage:100 mg/kg/d Administration:i.g. 6 weeks Result:Improved pathological structures of neurites and myelin.Increased SOD, CAT and GPX protein levels in sciatic nerves.Decrease aldose reductase level in sciatic nerves.

ONO-2235

Metabolic Enzyme/Protease

Aldose Reductase

Aldosereductase

Metabolic Disease

Diabetes

82159-09-9

319.3986

C15H13NO3S2

>98% (HPLC)

DMSO: ≥ 3.1 mg/mL

O=C(O)CN(C/1=O)C(SC1=C/C(C)=C/C2=CC=CC=C2)=S

3-Thiazolidineacetic acid, 5-[(2E)-2-methyl-3-phenyl-2-propen-1-ylidene]-4-oxo-2-thioxo-, (5Z)-

(-20℃)

With Ice Pack

≥ 2 years